By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom today raised its estimates for the number of billed MateriT21 Plus tests for 2012 to 40,000 as adoption of the test accelerated during the first quarter.

The San Diego-based firm had previously forecast 25,000 billings for the non-invasive fetal aneuploidy test for the year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.